Cargando…
Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma. Its unique pharmacology allows for IOP lowering as a result of di...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177382/ https://www.ncbi.nlm.nih.gov/pubmed/30323550 http://dx.doi.org/10.2147/OPTH.S154001 |
_version_ | 1783361844347404288 |
---|---|
author | Dasso, Lily Al-Khaled, Tala Sonty, Sriram Aref, Ahmad A |
author_facet | Dasso, Lily Al-Khaled, Tala Sonty, Sriram Aref, Ahmad A |
author_sort | Dasso, Lily |
collection | PubMed |
description | Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma. Its unique pharmacology allows for IOP lowering as a result of direct reduction in trabecular outflow resistance in addition to a decrease in episcleral venous pressure and aqueous humor production. The efficacy of netarsudil has been shown in animal studies and human clinical trials. It has been shown to be noninferior to the therapy with topical timolol in individuals with baseline IOP <25 mmHg. Importantly, netarsudil has been shown to reduce IOP to the same degree, regardless of baseline levels. There are no known systemic safety issues associated with netarsudil. The most common local adverse effects relate to conjunctival hyperemia. The once-daily dosing schedule is advantageous for individuals who have difficulties with medication adherence. Further studies of a combination of netarsudil and latanoprost agents are currently underway. |
format | Online Article Text |
id | pubmed-6177382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61773822018-10-15 Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date Dasso, Lily Al-Khaled, Tala Sonty, Sriram Aref, Ahmad A Clin Ophthalmol Review Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma. Its unique pharmacology allows for IOP lowering as a result of direct reduction in trabecular outflow resistance in addition to a decrease in episcleral venous pressure and aqueous humor production. The efficacy of netarsudil has been shown in animal studies and human clinical trials. It has been shown to be noninferior to the therapy with topical timolol in individuals with baseline IOP <25 mmHg. Importantly, netarsudil has been shown to reduce IOP to the same degree, regardless of baseline levels. There are no known systemic safety issues associated with netarsudil. The most common local adverse effects relate to conjunctival hyperemia. The once-daily dosing schedule is advantageous for individuals who have difficulties with medication adherence. Further studies of a combination of netarsudil and latanoprost agents are currently underway. Dove Medical Press 2018-10-04 /pmc/articles/PMC6177382/ /pubmed/30323550 http://dx.doi.org/10.2147/OPTH.S154001 Text en © 2018 Dasso et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Dasso, Lily Al-Khaled, Tala Sonty, Sriram Aref, Ahmad A Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date |
title | Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date |
title_full | Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date |
title_fullStr | Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date |
title_full_unstemmed | Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date |
title_short | Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date |
title_sort | profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177382/ https://www.ncbi.nlm.nih.gov/pubmed/30323550 http://dx.doi.org/10.2147/OPTH.S154001 |
work_keys_str_mv | AT dassolily profileofnetarsudilophthalmicsolutionanditspotentialinthetreatmentofopenangleglaucomaevidencetodate AT alkhaledtala profileofnetarsudilophthalmicsolutionanditspotentialinthetreatmentofopenangleglaucomaevidencetodate AT sontysriram profileofnetarsudilophthalmicsolutionanditspotentialinthetreatmentofopenangleglaucomaevidencetodate AT arefahmada profileofnetarsudilophthalmicsolutionanditspotentialinthetreatmentofopenangleglaucomaevidencetodate |